Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
RIBOMIC Announces the Sustained Efficacy in a Long-Term Administration Trial of Umedaptanib Pegol for Achondroplasia
Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2025(Based on Japanese GAAP)
[Delayed]RIBOMIC Plans to Initiate PhaseIII Clinical Trial of Umedaptanib Pegol for Achondroplasia in2026 Following the Ongoing PhaseII Clinical Trial
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Year Ended March 31 2025 (Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31 2024(Based on Japanese GAAP)
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2024(Based on Japanese GAAP)